Related Experiment Videos

Beta-blockers in chronic heart failure: considerations for selecting an agent

Marrick L Kukin1

  • 1The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029, USA. marrick.kukin@msnyuhealth.org

Mayo Clinic Proceedings
|November 21, 2002
PubMed

Insights

Beta-blocker therapy is crucial for managing chronic heart failure by inhibiting the sympathetic nervous system. While carvedilol and metoprolol succinate show similar survival benefits, choosing the right beta-blocker and proper titration are key for patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Chronic heart failure (CHF) is associated with heightened sympathetic nervous system activity, worsening cardiovascular function.
  • Long-term beta-blocker therapy mitigates this decline by targeting the neurohormonal pathway.
  • Beta-blockers are established treatments for New York Heart Association (NYHA) class II-III heart failure due to survival benefits.

Purpose of the Study:

  • To review the role of beta-blockers in managing chronic heart failure.
  • To compare the clinical outcomes of different beta-blockers, specifically carvedilol and extended-release metoprolol succinate.
  • To emphasize the importance of appropriate dosing and titration in beta-blocker therapy for heart failure.

Main Methods:

  • Review of existing large-scale studies and clinical trial data on beta-blocker therapy in heart failure.
  • Analysis of pharmacological properties and clinical outcomes associated with approved beta-blockers.
  • Examination of evidence regarding comparative efficacy and safety profiles.

Main Results:

  • Beta-blockers significantly improve survival and reduce mortality in patients with NYHA class II-III heart failure.
  • Carvedilol and extended-release metoprolol succinate demonstrate comparable risk reductions in overall and cause-specific mortality.
  • Limited evidence exists to support significant clinical outcome advantages of specific beta-blocker pharmacological properties over others.

Conclusions:

  • Beta-blockers are a cornerstone therapy for chronic heart failure, improving morbidity and mortality.
  • Current data suggest similar efficacy between carvedilol and extended-release metoprolol succinate in heart failure management.
  • Optimal patient outcomes depend on careful selection, appropriate dosing, and gradual titration of beta-blocker therapy.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...